Please login to the form below

Not currently logged in
Email:
Password:

Biogen Idec, Elan file Tysabri for first-line use

US and EU multiple sclerosis drug submissions follow companion diagnostic approval

Biogen Idec Elan Tysabri natalizumabBiogen Idec and Elan have filed to extend the uses of their multiple sclerosis (MS) drug Tysabri to include first-line therapy, which could represent a major new market for the blockbuster drug.

The filings for the new indication in the US and EU come on the back of the approval last year of a companion diagnostic that can be used to screen patients who may be susceptible to a rare but serious side effect of treatment.

The side effect - called progressive multifocal leukoencephalopathy (PML) and linked to infection with the JC virus - was first encountered in 2005 and resulted in Tysabri (natalizumab) being taken off the market just a year after it was launched. 

The product was however reintroduced in 2007 after regulators agreed that its benefits outweighed its risks in some MS patients. In trials, Tysabri has been shown to slow disability progression by between 42 and 54 per cent and reduce annualised relapse rates by 68 per cent.

The new applications request an expanded indication that would include first-line use for people living with certain relapsing forms of MS who have tested negative for antibodies to the JC virus.

Even with labelling restricting its use to second-line therapy Tysabri sales have been buoyant, reaching more than $400m in the third-quarter of 2012, and analysts have suggested first-line use could add another $1bn to the product's top line. 

Growth has been in the high single digits, but this has been pegged back by the availability of the JC virus test, which has led to a proportion of patients previously on the drug discontinuing therapy after a positive test result.

Biogen Idec and Elan's filing comes shortly after the launch of a second-generation JC virus assay with improved sensitivity and specificity to detect patients with low levels of JCV-specific antibodies.

As well as moving Tysabri into first-line use in relapsing MS, Elan and Biogen Idec are carrying out phase III studies to try to extend its uses to include patients with secondary progressive forms of the disease.

17th January 2013

From: Sales

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Kendle Healthcare

Company founder Neil Kendle was a pioneer in opinion leader engagement. In 2003, Neil brought together a small, dedicated team...

Latest intelligence

DEMAND DIVERSITY REPORT 02: Why is the LGBTQ+ community facing poorer health outcomes due to COVID-19?
We’re all aware that clinical trials have been discussed more widely since the COVID-19 pandemic. While that’s a great thing for raising awareness of clinical trials in general, it’s also...
CHECKLIST 04: Let’s make your patient recruitment strategies a success
From how to generate insights to define your audience to drilling down those all-important key messages, our checklist has everything you need to think of, covered....
Multichannel engagement and the need for greater understanding of European markets
By Laurence Olding and Georgina James...

Infographics